You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Multiple-stage activated-char filtration
SBC: Advanced Renewable Technology International Inc Topic: 02cLess than 1% of the worlds water is considered freshwater. Population growth and intensive use in cities and agro industrial activities threatens the depletion of this resource in many parts of the world. This depletion poses many major social and economic concerns. As a result, efforts have been made to develop economically viable technologies to make potable water from seawater or brackish water ...
STTR Phase I 2014 Department of Energy -
Uniform, High Intensity X-ray Source for Blood Irradiation
SBC: National Nanomaterials, Inc Topic: 22aThere is an ongoing effort to replace high activity radioactive sources that could pose a risk for use as terrorist weapons with non-radioisotope based technologies. Currently radioactive sources serve a number of critical needs including the treatment and diagnosis of disease, inspection and certification of critical mechanical structures, the sterilization of food and medical products, ...
STTR Phase I 2014 Department of Energy -
Next Generation Semiconductor-Based Radiation Detectors Using Cadmium Magnesium Telluride
SBC: BRIMROSE TECHNOLOGY CORP Topic: 23cAt present, CdZnTe is considered the material of choice for efficient, room temperature gamma-radiation detection systems used for the detection and identification of radionuclides. Despite the advances in CdZnTe materials technology during the last decade, the major impediments in the progress of - ray detection technology are the low yield of device quality materials and detectors, and the limit ...
STTR Phase I 2014 Department of Energy -
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ex vivo purging strategy for treatment of multiple myeloma
SBC: DNATRIX INC Topic: NCIDESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Small Molecule Therapies for Skeletal Muscle Atrophy
SBC: EMMYON, INC. Topic: NIADESCRIPTION (provided by applicant): Skeletal muscle atrophy is a widespread and serious medical problem. Frequent causes of skeletal muscle atrophy include orthopedic injuries, bed rest, advanced age, cancer, heart failure, COPD, diabetes, stroke, renalfailure, critical illness and spinal cord injury. Effects of skeletal muscle atrophy include weakness, reduced activity, falls, fractures, debili ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health